Eukaryote
Novo Nordisk Faces Setback in IRA Litigation, Vows to Appeal
Novo Nordisk, IRA lawsuit, Medicare price negotiations, legal setback, appeal
Gene Therapy Pioneer Jim Wilson Departs UPenn to Launch Two New Biotech Companies
Jim Wilson, UPenn, gene therapy, biotech companies, GEMMA Biotherapeutics, Franklin Biolabs
IRA Drug Price Reductions Unlikely to Harm Biotech Innovation, Studies Suggest
Inflation Reduction Act, IRA, drug price negotiations, biotech innovation, Medicare, pharmaceutical industry
Bayer’s NUBEQA Shows Promise in Prostate Cancer Treatment, Expanding Indications
NUBEQA, darolutamide, prostate cancer, metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, ARASENS trial, ARAMIS trial, Bayer, Orion Corporation
AstraZeneca Appeals IRA Loss, Reiterates Constitutional Challenge to Drug Price Negotiations
AstraZeneca, IRA, Medicare, Drug Price Negotiation, Constitutional Challenge, Appeal
Savara Raises $100 Million Following Lung Disease Treatment Breakthrough
Savara, Lung Disease, $100 Million Raise, Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Treatment
Roche Partners with Ascidian in $1.8 Billion RNA Exon Editing Deal for Neurological Diseases
Roche, Ascidian, RNA exon editing, neurological diseases, partnership, therapeutics
Geron’s Rytelo Receives FDA Approval for Lower-Risk Myelodysplastic Syndromes Treatment
Geron, Rytelo, FDA Approval, Blood Cancer, Myelodysplastic Syndromes, Telomerase Inhibitor, Imetelstat
FDA Delays Dupixent Decision for COPD by Three Months, EMA Recommends Approval
FDA, Dupixent, COPD, EMA, Regeneron, Sanofi, Priority Review, PDUFA, Boreas, Notus, Phase III Trials
ASCO24: Nimbus Unveils Promising Early Data for Next-Generation HPK1 Blocker in IO Therapies
ASCO24, Nimbus, Next-Generation IO Therapies, HPK1 Blocker, Early Data, Cancer Treatment, Immuno-Oncology, Clinical Trials.